🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chemnitz
Clinical trial register · Germany

Clinical Trials in Chemnitz, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 41 Essen 26 Ulm 23 Hamburg 22 Dresden 19
Narrow the registerReset
Recruitment status
Phase
Site location
Berlin41 Essen26 Ulm23 Hamburg22 Dresden19
All 107 locations
Target enrolment
to

Trials with a site in Chemnitz

10 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
NCT06847542Neovascular Age-related Macular Degeneration
Hoffmann-La Roche
Phase 3
250
Chemnitz, Düsseldorf, Göttingen, Hanover, Rostock, Würzburg
2025-11-27
Active, closed
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
NCT06863961Atopic Dermatitis
Hoffmann-La Roche
Phase 2
162
Freiburg im Breisgau, Bad Bentheim, Merzig, Chemnitz, Quedlinburg, Hamburg
2025-04-01
Active, closed
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
NCT06047080Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 3
1,130
Berlin, Brandenburg an der Havel, Chemnitz, Cologne, Düsseldorf, Erlangen, Essen, Frankfurt
2023-09-18
Active, closed
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
NCT05269004Multiple Sclerosis
Hoffmann-La Roche
Phase 3
1,300
Tübingen, Ulm, Bayreuth, Munich, Westerstede, Düsseldorf, Chemnitz, Leipzig
2022-05-03
Active, closed
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
NCT05091567Small-Cell Lung Cancer
Hoffmann-La Roche
Phase 3
660
Bad Berka, Berlin, Chemnitz, Essen, Georgsmarienhütte, Großhansdorf, Halle, Immenhausen
2021-11-18
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
NCT04961996Early Breast Cancer
Hoffmann-La Roche
Phase 3
4,170
Karlsruhe, Augsburg, Berlin, Chemnitz, Erlangen, Essen, Georgsmarienhütte, Hamburg
2021-08-27
Active, closed
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
NCT04546009Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche
Phase 3
992
Berlin, Chemnitz, Dresden, Essen, Georgsmarienhütte, Göttingen, Hamburg, Hanover
2020-10-09
Active, closed
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
NCT03456076Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche
Phase 3
257
Chemnitz, Georgsmarienhütte, Heidelberg, Immenhausen
2018-08-16
Active, closed
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT03178552Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2/3
1,000
Chemnitz, Gauting, Heidelberg, Wiesbaden
2017-09-22
Active, closed
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
NCT02486718Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 3
1,280
Bielefeld, Berlin, Braunschweig, Chemnitz, Frankfurt am Main, Großhansdorf, Hemer, Homburg
2015-10-31
Rows per page Showing 1–10 of 10
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 September 2026. https://priyalifescience.com/clinical-trials-germany/city/chemnitz

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 10 of those studies with a site in Chemnitz that also match the filters currently applied.

How many clinical trials are recruiting in Chemnitz?

1 of the 10 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 0 have not yet opened recruitment, 9 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Chemnitz), 10 studies
PhaseStudiesRecruitingShare
Phase 38180%
Phase 21010%
Phase 2/31010%

Most active sponsors

Lead sponsors with the most studies (Chemnitz)
Lead sponsorStudiesRecruiting
Hoffmann-La Roche101
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.